NCT04691648View on ClinicalTrials.gov

A Study to Assess the Safety of Xospata in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-Like Tyrosine Kinase 3 (FLT3) Mutation

CompletedOBSERVATIONAL
Enrollment

33

Participants

Timeline

Start Date

June 17, 2022

Primary Completion Date

May 4, 2025

Study Completion Date

May 4, 2025

Conditions
Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
Interventions
DRUG

Gilteritinib Exposure

Oral

Trial Locations (10)

10408

Site KR82006, Goyang-si

21565

Site KR82001, Incheon

26426

Site KR82013, Wŏnju

41944

Site KR82010, Daegu

47392

Site KR82011, Busan

58128

Site KR82003, Jeollanam-do

03080

Site KR82004, Seoul

03722

Site KR82005, Seoul

05505

Site KR82009, Seoul

07985

Site KR82007, Seoul

All Listed Sponsors
lead

Astellas Pharma Korea, Inc.

INDUSTRY